

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9939)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF PATIENT ENROLMENT IN PHASE II CLINICAL TRIAL OF KX-826 FOR TREATMENT OF MALE AGA PATIENTS IN THE US

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that on 1 August 2022, the Company has completed the enrolment of 121 patients for its phase II clinical trial (the “**Phase II Clinical Trial**”) of pyrilutamide (“**KX-826**”) in the United States (the “**US**”) for the treatment of male androgenetic alopecia (“**AGA**”) patients.

The Phase II Clinical Trial (NCT05218642) is a randomized, double-blind, placebo-controlled, parallel group study designed to evaluate the efficacy and safety of KX-826 for the treatment of male AGA patients. The primary endpoint for the trial is the change from baseline in non-vellus target area hair counts (“**TAHC**”) at week 24 in comparison to placebo.

KX-826 is an androgen receptor (“**AR**”) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. In addition to the Phase II Clinical Trial, the Company is also conducting a phase III clinical trial of KX-826 in China for male AGA patients.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED

Dr. Youzhi Tong

Chairman, Executive Director and Chief Executive Officer

Hong Kong, 3 August 2022

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*